



2nd June, 2026

BSE Limited PJ. Towers, Dalal Street Mumbai - 400 001. Script Code: 524212	National Stock Exchange of India Ltd, Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051. Script Code: WANBURY
---------------------------------------------------------------------------------------------------	----------------------------------------------------------------------------------------------------------------------------------------------------------

Dear Sir/Madam,

Sub: Press Release - on Q4 & year ended FY2026 Audited Financial Results

As per Regulation 30 of SEBI LODR, please find attached herewith copy of press release on Audited Financial Results (AFR) for the quarter and full year ended 31st March, 2026.

This is for your information and record.

Thanking you.

Yours faithfully,
For Wanbury Ltd



Jitendra J. Gandhi
Company Secretary



Press Release

Wanbury Limited Delivers 117% YoY PAT Growth in FY26; EPS more than doubles to ₹20.55

Builds Momentum for Next Phase of Growth with New API Launches and Zero-Observation Regulatory Clearance.

Mumbai, 2nd June 2026: Wanbury Limited, a pharmaceutical company with a global API presence and domestic branded formulations portfolio, today announced its audited financial results for the fourth quarter and full year ended 31st March 2026.

FY26 Performance Highlights

Metric	FY26	FY25	YoY Change
Revenue from Operations	₹650.3 Cr	₹599.5 Cr	+8.5%
EBITDA*	₹107.7 Cr	₹79.8 Cr	+34.9%
EBITDA Margin	16.5%	13.2%	+330 bps
PAT	₹66.1 Cr	₹30.5 Cr	+116.6%
PAT Margin	10.2%	5.1%	+509 bps
EPS	₹20.55	₹9.32	+122%

**Includes Other Income*

Q4 FY26 Snapshot

Metric	Q4 FY26	QoQ Change	YoY Change
Revenue	₹164.6 Cr	+1.3%	-4.3%
EBITDA*	₹30.1 Cr	+11.9%	-4.5%
PAT	₹21.7 Cr	+37.7%	+7.2%
PAT Margin	13.2%	+150 bps YoY	

**Includes Other Income*





Key Highlights:

Financial Performance:

- **FY26 PAT surges 117% YoY to ₹66.1 Cr**, with PAT margin expanding 509 bps to 10.2%.
- **EPS more than doubles from ₹9.32 to ₹20.55** in FY26, reflecting strong bottom-line growth.
- **EBITDA grows 34.9% YoY to ₹107.7 Cr** in FY26, driven by revenue growth, favourable product mix, better yields, procurement efficiencies, and process optimization.
- **Q4 FY26 gross margin expands 887 bps YoY to 60.4%**, despite revenue impact from West Asia crisis in March 2026.

Business & Operational Momentum

- **New Anaesthetic API launched** from Tanuku facility after CAPEX completion. Commercial dispatches to Europe commenced February 2026.
- **Pipeline strengthens** with upcoming specialty APIs: Dextromethorphan HBr, Rivaroxaban, and Sitagliptin.
- **Operational efficiency** continues to improve as the company continued to invest in debottlenecking, process optimisation and manufacturing upgrades to improve capacity, operating leverage and scalability.
- **Zero observations** received in MFDS, Korea inspection conducted 7–9 April 2026. Previously, zero observations received in USFDA inspection at Patalganga facility, and zero observations in ANVISA Brazil inspection.
- **ANVISA, Brazil approval** secured for Sertraline Form II, deepening regulated market access.
- **Formulations turnaround continues** with improved performance and new launches across paediatric, nutraceutical, and specialty categories.
- **SAP HANA S4 implemented** to drive operational efficiencies across the organization.

Q4 FY26 Context

Revenue from operations for Q4 FY26 stood at ₹164.6 crore, compared to ₹172.0 crore in Q4 FY25, impacted by the crisis in West Asia in late February, which disrupted API export dispatches during March. As a largely export-led business, this affected quarterly revenue. Gross margin increased 11.1% YoY to ₹99.5 crore in Q4 FY26. Gross margin expanded by 887 bps to 60.4%, supported by better product mix and internal cost efficiency initiatives. EBITDA (including other income) stood at ₹30.1 crore, compared to ₹31.5 crore in Q4 FY25.





The lower absolute EBITDA reflects the slight decline in revenue for the quarter. EBITDA margin, however, improved by 14 bps YoY to 18.2%, supported by operational efficiencies and better gross margins. PAT stood at ₹21.7 crore, compared to ₹20.3 crore in Q4 FY25, a growth of 7.2% YoY, even after absorbing a one-time exceptional charge of ₹3.6 crore relating to the implementation of new labour codes. PAT margin improved by 150 bps YoY to 13.2% in Q4 FY26, compared to 11.7% in Q4 FY25.

Management Commentary

Mr. Mohan Rayana, Director, Wanbury Limited, said:

“FY26 was an important year for Wanbury. We strengthened business fundamentals through operational efficiencies, debottlenecking, balance sheet improvement, and expansion of our API and formulations portfolio. Improved plant utilisation, enhanced product yields, and procurement efficiencies supported better EBITDA margins.

The fourth quarter saw a revenue decline due to the West Asia crisis impacting API export dispatches in March. This aside, we were on track to deliver growth on the back of new product launches in Q4.

A key milestone was the launch of our new Anaesthetic API with commercial dispatches beginning February 2026. Clearing the MFDS, Korea inspection with zero observations validates our compliance systems. We will continue our API growth journey in FY27 with recent launches and a strong pipeline, while the formulations business will operate from a stronger footing supported by new launches and an improved go-to-market strategy.”

About Wanbury Limited

Established in 1988, Wanbury Limited is listed on NSE (Code: WANBURY) and BSE (Code: 524212). The company has a strong global API presence with exports to over 50 countries and a pan-India formulations footprint. Wanbury operates USFDA and EUGMP approved facilities at Tanuku, Andhra Pradesh and Patalganga, Maharashtra.

API Portfolio: Metformin, Sertraline, Tramadol, Diphenhydramine, Mefenamic Acid, Paroxetine, Ketamine Hydrochloride, and others in pipeline. Clients include leading global generic players.

Formulations Portfolio: Presence across cough and cold, gynaecology, orthopaedics, nutraceuticals, gastrointestinal, anti-inflammatory, and analgesics.

For more details: <https://www.wanbury.com/>





Investor & Media Contacts

Jitendra J. Gandhi
Company Secretary
Wanbury Limited
jitendra.gandhi@wanbury.com

Investor Relations Advisors

Sayam Pokharna
TIL Advisors Private Limited
sayam@theinvestmentlab.in

PR Agency

Smit Shah / Devyanshi Dave
Adfactors PR
smit.shah@adfactorspr.com
devyanshi.dave@adfactorspr.com

Caution Concerning Forward- Looking Statements:

This document may contain statements, which reflect management's current views and estimates and could be construed as forward-looking statements. The future involves certain risks and uncertainties and could cause actual results to differ materially from the current views being expressed. Potential risks and uncertainties include factors such as general economic conditions, foreign exchange fluctuation, pricing pressures, competition and regulatory developments.

